Monoclonal antibody therapy of pancreatic cancer with cetuximab: potential for immune modulation.

Journal of Immunotherapy
Eric LuedkeWilliam E Carson

Abstract

Pancreatic cancer is a devastating disease, with a median survival of around 6 months for patients with stage IV disease. The epidermal growth factor receptor (EGFR, or HER1) belongs to the erbB receptor tyrosine kinase family. HER1-mediated cell signaling has been shown to play a major role in promoting tumor proliferation, angiogenesis, metastasis, and evasion of apoptosis. Over-expression of HER1 is observed in multiple human malignancies, including colorectal, lung, breast and pancreatic cancers. In pancreatic carcinoma, over-expression of HER1 is observed in greater than 70% of patients and is associated with a poor prognosis and a significant decrease in survival. Cetuximab (Erbitux) is a chimeric monoclonal antibody (mAb) that binds to the extracellular domain of the HER1 molecule preventing ligand binding and promoting internalization and subsequent degradation of the HER1 receptor. Cetuximab has shown anti-tumor activity either alone or in combination with other agents and is currently FDA approved for use in both squamous cell carcinoma of the head and neck (SCCHN) and colorectal carcinoma. Research efforts continue to elucidate a possible role for cetuximab in the treatment of pancreatic cancer. Despite promising pre...Continue Reading

References

Mar 31, 2000·Nature Medicine·R A ClynesJ V Ravetch
Feb 28, 2002·Annual Review of Immunology·Carlos Vilches, Peter Parham
Oct 9, 2002·The Journal of Clinical Investigation·Robin PariharWilliam E Carson
Nov 7, 2002·International Journal of Radiation Oncology, Biology, Physics·Donald J BuchsbaumKevin P Raisch
Feb 5, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Fortunato CiardielloGiampaolo Tortora
Mar 3, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzRobert J Mayer
Jul 1, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Henry Q XiongJames L Abbruzzese
Jul 13, 2004·Science·Joseph N Blattman, Philip D Greenberg
Jul 23, 2004·The New England Journal of Medicine·David CunninghamEric Van Cutsem
Jan 5, 2005·The Journal of Experimental Medicine·Rong ZengWarren J Leonard
May 3, 2005·Nature Reviews. Cancer·Nancy E Hynes, Heidi A Lane
Feb 10, 2006·The New England Journal of Medicine·James A BonnerK Kian Ang
Jun 17, 2006·The Journal of Clinical Investigation·John PesceThomas A Wynn
Feb 10, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Paula M FracassoChristopher R Garrett
Apr 21, 2007·Cancer Immunology, Immunotherapy : CII·Emma di CarloSilvano Ferrini
Jun 19, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Ian D DavisGrant A McArthur
Oct 27, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Julie M RodaWilliam E Carson
Nov 16, 2007·The New England Journal of Medicine·Derek J JonkerMalcolm J Moore
Dec 14, 2007·The Lancet Oncology·Stefano CascinuUNKNOWN Italian Group for the Study of Digestive Tract Cancer (GISCAD)
Mar 14, 2008·The New England Journal of Medicine·Fortunato Ciardiello, Giampaolo Tortora
Mar 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Antonino MusolinoAndrea Ardizzoni
Jan 16, 2010·Annals of the New York Academy of Sciences·Neela S Bhave, William E Carson
Feb 12, 2010·Investigational New Drugs·Cheryl HoAngela M Davies
Jul 8, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philip A PhilipCharles D Blanke
Feb 16, 2011·The Journal of Immunology : Official Journal of the American Association of Immunologists·Alena Cristina Jaime-RamirezWilliam E Carson

❮ Previous
Next ❯

Citations

Aug 7, 2013·Journal of Cancer Research and Clinical Oncology·Thomas C WehlerCarl C Schimanski
Dec 15, 2015·Advanced Drug Delivery Reviews·Bora JangHyukjin Lee
Aug 11, 2015·Advances in Biological Regulation·Timothy L FitzgeraldJames A McCubrey
Dec 23, 2014·Future Oncology·Madappa Kundranda, Toufic Kachaamy
May 17, 2013·Molecular Pharmaceutics·Han Han, Mark E Davis
Nov 23, 2019·Current Drug Metabolism·Henu K VermaSmaranika Pattnaik
Jul 19, 2016·International Journal of Cancer. Journal International Du Cancer·Mara SaccomanoJoanna Napp
Jan 1, 2013·Personalized Medicine·Krissi DanielssonRoland Andersson
Jul 21, 2016·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Elizabeth L McMichaelWilliam E Carson
Feb 7, 2021·Journal of Clinical Medicine·Andres Garcia-SampedroPilar Acedo

❮ Previous
Next ❯

Related Concepts

Related Feeds

Apoptosis in Cancer

Apoptosis is an important mechanism in cancer. By evading apoptosis, tumors can continue to grow without regulation and metastasize systemically. Many therapies are evaluating the use of pro-apoptotic activation to eliminate cancer growth. Here is the latest research on apoptosis in cancer.

Apoptosis

Apoptosis is a specific process that leads to programmed cell death through the activation of an evolutionary conserved intracellular pathway leading to pathognomic cellular changes distinct from cellular necrosis

Cell Signaling by Tyrosine Kinases

Receptor tyrosine kinases (RTKs) are the high-affinity cell surface receptors for many polypeptide growth factors, cytokines, and hormones. RTKs have been shown not only to be key regulators of normal cellular processes but also to have a critical role in the development and progression of many types of cancer. Discover the latest research on cell signaling and RTK here.

Angiogenesis Inhibitors to Treat Cancer

Cancer treatments including angiogenesis inhibitors prevent tumor cells from receiving nutrients and oxygen. Here is the latest research on angiogenesis inhibitors for the treatment of cancer.